Treatment Concerns for Bullous Pemphigoid in the Covid-19 Pandemic Era

Treatment Concerns for Bullous Pemphigoid in the Covid-19 Pandemic Era Publisher Pubmed

Azimi SZ¹ ; Firooz A¹ ; Murrell DF² ; Daneshpazhooh M³

Show Affiliations

1. Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Dermatology, University of New South Wales, Sydney, NSW, Australia
3. Department of Dermatology, Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Dermatologic Therapy Published:2020

Abstract

Bullous pemphigoid (BP) is the most common autoimmune blistering disease with subepidermal involvement, typically affecting the elderly. It has spontaneous remissions and exacerbations with significant morbidity. A novel coronavirus called severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the new universal coronavirus disease 2019 (COVID-19) pandemic. The pandemic made concerns, especially about immunosuppressive therapy. In this article, we reviewed the management of BP in the COVID-19 pandemic era. The data about the best management of autoimmune bullous diseases like BP, during the outbreak of COVID-19, are evolving and updated every day. © 2020 Wiley Periodicals LLC.

Related Docs

View other Related Docs

1. Multisystem Inflammatory Syndrome and Autoimmune Diseases Following Covid-19: Molecular Mechanisms and Therapeutic Opportunities, Frontiers in Molecular Biosciences (2022)

2. Pharmacological Treatments of Covid-19, Pharmacological Reports (2020)

3. The Efficacy of Rituximab in Patients With Mucous Membrane Pemphigoid, Journal of Dermatological Treatment (2022)

4. Bullous Pemphigoid, Nature Reviews Disease Primers (2025)

5. Adverse Outcome and Severity of Covid-19 in Patients With Autoimmune Bullous Diseases: A Historical Cohort Study, Dermatologic Therapy (2022)

6. Authors' Reply to the Comment “Treatment Considerations for Patients With Pemphigus During the Covid-19 Pandemic”, Journal of the American Academy of Dermatology (2021)

7. Dietary Patterns and Micronutrients in Respiratory Infections Including Covid-19: A Narrative Review, BMC Public Health (2024)

8. The Role of Bacterial and Fungal Human Respiratory Microbiota in Covid-19 Patients, BioMed Research International (2021)

Experts (# of related papers)

View all Related Experts

Maryam Daneshpajooh (8)

Hamid Reza Mahmoodi (4)

Style	Citing Format
MLA	Azimi SZ, et al.. "Treatment Concerns for Bullous Pemphigoid in the Covid-19 Pandemic Era." Dermatologic Therapy, vol. 33, no. 6, 2020, pp. -.
APA	Azimi SZ, Firooz A, Murrell DF, Daneshpazhooh M (2020). Treatment Concerns for Bullous Pemphigoid in the Covid-19 Pandemic Era. Dermatologic Therapy, 33(6), -.
Chicago	Azimi SZ, Firooz A, Murrell DF, Daneshpazhooh M. "Treatment Concerns for Bullous Pemphigoid in the Covid-19 Pandemic Era." Dermatologic Therapy 33, no. 6 (2020): -.
Harvard	Azimi SZ et al. (2020) 'Treatment Concerns for Bullous Pemphigoid in the Covid-19 Pandemic Era', Dermatologic Therapy, 33(6), pp. -.
Vancouver	Azimi SZ, Firooz A, Murrell DF, Daneshpazhooh M. Treatment Concerns for Bullous Pemphigoid in the Covid-19 Pandemic Era. Dermatologic Therapy. 2020;33(6):-.
BibTex	@article{ author = {Azimi SZ and Firooz A and Murrell DF and Daneshpazhooh M}, title = {Treatment Concerns for Bullous Pemphigoid in the Covid-19 Pandemic Era}, journal = {Dermatologic Therapy}, volume = {33}, number = {6}, pages = {-}, year = {2020} }
RIS	TY - JOUR AU - Azimi SZ AU - Firooz A AU - Murrell DF AU - Daneshpazhooh M TI - Treatment Concerns for Bullous Pemphigoid in the Covid-19 Pandemic Era JO - Dermatologic Therapy VL - 33 IS - 6 SP - EP - PY - 2020 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract